

Supplementary Table 3. Survival outcomes for patients receiving different systemic treatments.

Treatments	1st-line			2nd-line			3rd-line		
	n	mPFS1	mOS1	n	mPFS2	mOS2	n	mPFS3	mOS3
ICI+TKI	44	19	NR	18	21.7	NR	4	13.5	13.5
TKI monotherapy	18	9.3	25.7	8	9.1	16.5	1	NR	NR
TKI+mTORi	2	4	NR	2	2	18.8	0	-	-
Chemotherapy monotherapy	2	2.5	NR	0	-	-	0	-	-
Bevacizumab+Erlotinib	1	17.6	17.6	0	-	-	0	-	-
ICI+Chemotherapy	1	3	-	0	-	-	0	-	-
mTORi monotherapy	0	-	-	1	1	15.2	1	NR	NR
ICI monotherapy	0	-	-	1	18.1	NR	0	-	-
ICI+ICI	0	-	-	1	NR	NR	0	-	-
CDK4/6i monotherapy	0	-	-	0	-	-	1	4.2	4.2
ICI+TKI+PARPi	0	-	-	0	-	-	1	NR	NR

mPFS, median progression-free survival; mOS, median overall survival; ICI, immune check point; TKI, tyrosine kinase inhibitor; NR, not reached; mTORi, mTOR inhibitor; CDK4/6i, CDK4/6 inhibitor; ORR, objective response rate; DCR, disease control rate; PD, progressive disease.